Bottom line
Is RMDFX a good fund? The bottom line
RMDFX is a managed allocation / balanced mutual fund from Aspiriant.
Its expense ratio is 5.35% — about $535 a year on every $10,000 invested, more expensive than 100% of allocation / balanced funds we track.
It returned +18.8% over one year, +5.8% a year over five years, +5.0% a year over ten (as of Dec 31, 2025, per its prospectus).
With $1.1 billion in net assets and 15 holdings, its largest position is GMO Benchmark-Free Allocation Fund (26.4%) and the top 10 make up 86.5% of the portfolio.
What stands out
- No front-end sales load
What to watch
- Expensive for its category (5.35%)
- Concentrated: top 10 holdings are 86.5% of assets
Updated Nov 19, 2026
What RMDFX invests in
The Aspiriant Defensive Allocation Fund (the Fund or Defensive Allocation Fund) seeks to achieve long-term investment returns with lower risk and lower volatility than the stock market, and with relatively low correlation to stock and bond market indexes.
The Defensive Allocation Fund is a fund-of-funds that seeks to provide an investment return that has lower volatility than traditional asset classes (i.e., public equity and investment grade bonds) by combining several non-traditional or alternative asset class exposures, including investments that focus on a specialized asset class such as long-short strategies. Non-traditional or alternative asset classes have tended over time to have a lower correlation with the broad U.S. stock and bond markets. The Fund allocates its assets among a variety of non-traditional or alternative asset classes listed below so as to capture diversifying returns from these non-traditional or alternative sources. The Defensive Allocation Fund invests primarily in Underlying Funds and may, to a limited extent, invest in separately managed accounts (SMAs), which are private portfolios of securities for…
From the fund's prospectus (filed Jul 29, 2026).
RMDFX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| RMDFX | +18.8% | +5.8% | +5.0% |
| Allocation / Balanced median | +11.0% | +5.7% | +6.7% |
Source: Fund prospectus, as of Dec 31, 2025
What RMDFX costs
On a $10,000 investment, RMDFX's 5.35% expense ratio costs about $535 a year. The prospectus estimates $5,311 in total costs over 10 years (assuming 5% annual returns). The median allocation / balanced fund charges 0.91%.
RMDFX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | GMO Benchmark-Free Allocation Fund | 26.36% |
| 2 | Wilshire Bridgewater Managed Alpha (Ireland) Fund | 12.15% |
| 3 | iShares Gold Trust | 7.38% |
| 4 | Victory Pioneer Multi-Asset Income Fund | 7.33% |
| 5 | Lazard Global Investment Funds plc - Lazard Rathmore Alternative Fund | 7.02% |
| 6 | Millennium International Ltd. | 6.43% |
| 7 | Eaton Vance Global Macro Absolute Return Advantage Fund | 6.26% |
| 8 | GMO Investments ICAV - GMO Equity Dislocation Investment Fund | 5.63% |
| 9 | Elliott Associates LP | 4.31% |
| 10 | State Street Bridgewater All Weather ETF | 3.64% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 86.5% of the fund. See all top 25 holdings and asset mix →